AbbVie reports positive topline from Phase 3 CERVINO trial
AbbVie says Phase 3 CERVINO TOPLINE results are positive, with etentamig showing improved response rate and progression-free survival in relapsed/refractory multiple myeloma.
Story updates
01:17:09 PM UTC
SquawkNews
AbbVie: Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results To Be Presented Sept 23-26
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.